Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

F. Robbins, Paul; A. Morgan, Richard; A. Feldman, Steven; C. Yang, James; M. Sherry, Richard; E. Dudley, Mark; R. Wunderlich, John; Nahvi, Azam; J. Helman, Lee; L. Mackall, Crystal; S. Kammula, Udai; S. Hughes, Marybeth; P. Restifo, Nicholas; Raffeld, Mark; Richard Lee, Chyi‐Chia; Lévy, Catherine; F. Li, Yong; El‐Gamil, Mona; Schwarz, Susan; M. Laurençot, Carolyn; A. Rosenberg, Steven

doi:10.1200/jco.2010.32.2537

Public

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

Published in Journal of Clinical Oncology • Feb 1, 2011

Authors:

Paul F. Robbins

Richard A. Morgan

Steven A. Feldman

Abstract

PURPOSE: Adoptive immunotherapy using tumor-infiltrating lymphocytes represents an effective cancer treatment for patients with metastatic melanoma. The NY-ESO-1 cancer/testis antigen, which is expressed in 80% of patients with synovial cell sarcoma and approximately 25% of patients with melanoma an...

Subject

Medicine

Synovial sarcoma

Melanoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!